AstraZeneca PLC on Wednesday said it has received positive results from interim analysis of the DUO-O phase 3 trial of its Imfinzi drug.

The Cambridge, UK-based pharmaceutical company said the analysis showed that a combination of Imfinzi, alongside Lynparza, chemotherapy and bevacizumab met its primary endpoint.

It showed a ‘statistically significant and clinically meaningful’ improvement in progression-free survival when compared with treatment with just chemotherapy and bevacizumab.

The company said patients newly diagnosed with advanced high-grade epithelial ovarian cancer without tumour BRCA mutations were treated with Imfinzi with chemotherapy and bevacizumab, followed by maintenance therapy of Imfinzi, Lynparza and bevacizumab.

Durvalumab, sold under the brand Imfinzi, is the only approved immunotherapy and the global standard of care for stage 3 non-small cell lung cancer which has not progressed after chemoradiation therapy.

Astrazeneca added that a combination of Imfinzi with chemotherapy and bevacizumab showed a numerical improvement in progression-free survival compared to the control arm, but did not reach statistical significance at the interim stage.

Overall survival and other secondary endpoints were immature at the time of the interim analysis, the firm said.

Susan Galbraith, executive vice president of oncology R&D said: ‘While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients.’

AstraZeneca shares rose 1.2% to 11,380.00 pence each in London on Wednesday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.